Revolo Biotherapeutics (Revolo Bio), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, announced that it has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) to commence two phase 2 clinical trials to evaluate its immune-resetting drug candidate,
